Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies

Exclusion Criteria

• •Any cancer therapy in the last 4 weeks or limited palliative radiation \<2 weeks
• •Patients with HBV, HCV or HIV infection
• •Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic hematologic stem cell transplant within 12 months.
• •Previous therapy with GS-1101 (CAL-101, idelalisib), IPI-145, TGR-1202 or any drug that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or BTK Inhibitor (including Ibrutinib).
• •Patients on immunosuppressive therapy including systemic corticosteroids.
• •Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium or heparin, etc.).
• •Patients with known history of liver disorders.
• •Patients with uncontrolled Diabetes Type I or Type II
• •Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.
• •Women who are pregnant or lactating.